Emily  Gottschalk net worth and biography

Emily Gottschalk Biography and Net Worth

Director of Anixa Biosciences
Emily Gottschalk is an experienced marketer with over 30 years of developing products for the consumer marketplace.  She is the founder and CEO of The Garr Group, Inc, a diverse entertainment and new product development company that sells entertainment and general merchandise to the mass, specialty and on-line market.  Mass retail customers include Walmart, Sam’s, Walgreens, K-mart, Target, and others.  Past partners include AARP, Intel, Walmart, Disney, Fox, Kellogg’s, Kraft and MLB.  Ms. Gottschalk co-founded IdeationUSA, LLC, a product development company focused on bringing innovative electronics to the consumer market.  IdeationUSA identifies “white space” opportunities in the marketplace and defines and develops products that uniquely touch consumers lives.  Ideation is equally focused on brick and mortar, on-line and emerging distribution channels.  Previously, she was Marketing Director of Zany Brainy, a children’s educational toy store that she launched.  Since 1997, Ms. Gottschalk’s companies have produced over 150 million CD’s/DVD’s to the US retail market, developed a proprietary Android tablet called “RealPad, by AARP” with Intel and has created private label brands across the home and craft market.  She is a graduate of Cornell University’s School of Hotel Administration and serves on the board of several philanthropic organizations.

How do I contact Emily Gottschalk?

The corporate mailing address for Ms. Gottschalk and other Anixa Biosciences executives is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. Anixa Biosciences can also be reached via phone at (408) 708-9808 and via email at [email protected]. Learn More on Emily Gottschalk's contact information.

Has Emily Gottschalk been buying or selling shares of Anixa Biosciences?

Emily Gottschalk has not been actively trading shares of Anixa Biosciences over the course of the past ninety days. Most recently, on Friday, April 23rd, Emily Gottschalk bought 10,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $4.49 per share, with a total value of $44,900.00. Learn More on Emily Gottschalk's trading history.

Who are Anixa Biosciences' active insiders?

Anixa Biosciences' insider roster includes Arnold Baskies (Director), Emily Gottschalk (Director), Amit Kumar (CEO), and Lewis Titterton, Jr. (Director). Learn More on Anixa Biosciences' active insiders.

Are insiders buying or selling shares of Anixa Biosciences?

In the last year, Anixa Biosciences insiders bought shares 4 times. They purchased a total of 60,509 shares worth more than $202,149.52. In the last year, insiders at the sold shares 1 times. They sold a total of 11,800 shares worth more than $42,126.00. The most recent insider tranaction occured on April, 9th when Director Lewis H Titterton Jr bought 15,009 shares worth more than $49,229.52. Insiders at Anixa Biosciences own 22.6% of the company. Learn More about insider trades at Anixa Biosciences.

Information on this page was last updated on 4/9/2024.

Emily Gottschalk Insider Trading History at Anixa Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2021Buy10,000$4.49$44,900.00
See Full Table

Emily Gottschalk Buying and Selling Activity at Anixa Biosciences

This chart shows Emily Gottschalk's buying and selling at Anixa Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anixa Biosciences Company Overview

Anixa Biosciences logo
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Read More

Today's Range

Now: $3.25
Low: $3.13
High: $3.32

50 Day Range

MA: $3.36
Low: $2.98
High: $4.05

2 Week Range

Now: $3.25
Low: $2.75
High: $5.13

Volume

219,833 shs

Average Volume

142,462 shs

Market Capitalization

$103.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84